Nuvation Bio’s Taletrectinib Recommended in NCCN CNS Guidelines with 76.5% Intracranial Response
The NCCN updated Clinical Practice Guidelines for CNS Cancers on April 24, 2026 to include taletrectinib as a systemic therapy option for ROS1-positive NSCLC patients with brain metastases. Taletrectinib previously gained FDA approval and demonstrated intracranial response rates of 76.5% in TKI-naive and 65.6% in TKI-pretreated patients.
1. NCCN CNS Guideline Update
On April 24, 2026 the NCCN Clinical Practice Guidelines for Central Nervous System Cancers added taletrectinib as a systemic therapy option for ROS1-positive NSCLC patients with brain metastases, marking its second guideline inclusion following the NSCLC guidelines in June 2025.
2. Demonstrated Intracranial Efficacy
In clinical evaluations, taletrectinib achieved a 76.5% intracranial overall response rate in TKI-naive patients and 65.6% in TKI-pretreated patients, demonstrating significant brain penetrance and durable responses in heavily affected populations.
3. Commercial Outlook and Adoption
This dual recommendation in both NSCLC and CNS guidelines enhances taletrectinib’s market potential for ROS1-positive NSCLC with CNS involvement, potentially driving adoption, payer coverage and revenue growth as a preferred next-generation ROS1 inhibitor.